Business Context and Reporting Period
This Form 8-K filing by Neoleukin Therapeutics, Inc. (NLTX) reports on the results of the 2022 Annual Meeting of Stockholders held on May 12, 2022. The company is incorporated in Delaware and trades on The Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
The following proposals were adopted at the Annual Meeting:
- Election of Directors: Two Class II Directors were elected to three-year terms expiring in 2025:
- Jonathan G. Drachman, M.D.: 24,103,788 shares For; 108,548 shares Withheld.
- Sarah B. Noonberg, M.D., Ph.D.: 23,994,699 shares For; 217,637 shares Withheld.
- Ratification of Auditors: Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- 30,382,561 shares For; 42,629 shares Against; 13,977 shares Abstaining.
- Executive Compensation: A non-binding advisory vote approved the compensation paid to named officers.
- 22,484,586 shares For; 1,701,779 shares Against; 25,971 shares Abstaining.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the tenure and qualifications of the newly elected directors, Jonathan G. Drachman and Sarah B. Noonberg.
- Confirm the engagement of Deloitte & Touche LLP for the 2022 fiscal year audit.
- Review the specific compensation details for named officers referenced in the advisory vote.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.